143 related articles for article (PubMed ID: 11125232)
1. Bacteroides fragilis-induced intra-abdominal abscess in an experimental model treated with telithromycin (HMR 3647).
Thadepalli H; Chuah SK; Qazi S; Thadepalli F; Gollapudi SV
Chemotherapy; 2001; 47(1):43-9. PubMed ID: 11125232
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of telithromycin in the treatment of experimental Bacteroides fragilis intraabdominal abscess in the senescent mice.
Thadepalli H; Chuah SK; Vidad A; Gollapudi S
Infez Med; 2004 Mar; 12(1):44-50. PubMed ID: 15329528
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic efficacy of moxifloxacin, a new quinolone, in the treatment of experimental intra-abdominal abscesses induced by Bacteroides fragilis in mice.
Thadepalli H; Chuah SK; Gollapudi S
Chemotherapy; 2004 Jun; 50(2):76-80. PubMed ID: 15211081
[TBL] [Abstract][Full Text] [Related]
4. Activity of telithromycin (HMR 3647) against anaerobic bacteria compared to those of eight other agents by time-kill methodology.
Credito KL; Ednie LM; Jacobs MR; Appelbaum PC
Antimicrob Agents Chemother; 1999 Aug; 43(8):2027-31. PubMed ID: 10428930
[TBL] [Abstract][Full Text] [Related]
5. In vitro and in vivo antibacterial activities of telithromycin.
Mikamo H; Yin XH; Ninomiya M; Tamaya T
Chemotherapy; 2003 May; 49(1-2):62-5. PubMed ID: 12714813
[TBL] [Abstract][Full Text] [Related]
6. Relative antibacterial efficacy of clindamycin and metronidazole against Bacteroides fragilis in vitro and in experimentally infected mice.
Dijkmans BA; Vaishnav J; Mattie H
Chemotherapy; 1985; 31(4):297-303. PubMed ID: 4028873
[TBL] [Abstract][Full Text] [Related]
7. Synergism between penicillin, clindamycin, or metronidazole and gentamicin against species of the Bacteroides melaninogenicus and Bacteroides fragilis groups.
Brook I; Coolbaugh JC; Walker RI; Weiss E
Antimicrob Agents Chemother; 1984 Jan; 25(1):71-7. PubMed ID: 6142680
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic efficacy and pharmacokinetic properties of rifampicin in a Bacteroides fragilis intra-abdominal abscess.
Fu KP; Lasinski ER; Zoganas HC; Kimble EF; Konopka EA
J Antimicrob Chemother; 1984 Dec; 14(6):633-40. PubMed ID: 6520063
[TBL] [Abstract][Full Text] [Related]
9. Effect of prophylactic antibiotics upon mixed infections with Bacteroides fragilis.
Brook I
Surg Gynecol Obstet; 1987 Dec; 165(6):491-5. PubMed ID: 3317944
[TBL] [Abstract][Full Text] [Related]
10. In vitro susceptibility and in vivo efficacy of antimicrobials in the treatment of Bacteroides fragilis-Escherichia coli infection in mice.
Brook I
J Infect Dis; 1989 Oct; 160(4):651-6. PubMed ID: 2677161
[TBL] [Abstract][Full Text] [Related]
11. Use of cephalosporins for prophylaxis and therapy of polymicrobial infection in mice.
Brook I
Antimicrob Agents Chemother; 1993 Jul; 37(7):1531-5. PubMed ID: 8363386
[TBL] [Abstract][Full Text] [Related]
12. Relative efficacy and critical interval of antimicrobial agents in experimental infections involving bacteroides fragilis.
Bartlett JG; Dezfulian M; Joiner K
Arch Surg; 1983 Feb; 118(2):181-4. PubMed ID: 6849635
[TBL] [Abstract][Full Text] [Related]
13. In vivo efficacy of trovafloxacin (CP-99,217), a new quinolone, in experimental intra-abdominal abscesses caused by Bacteroides fragilis and Escherichia coli.
Thadepalli H; Reddy U; Chuah SK; Thadepalli F; Malilay C; Polzer RJ; Hanna N; Esfandiari A; Brown P; Gollapudi S
Antimicrob Agents Chemother; 1997 Mar; 41(3):583-6. PubMed ID: 9055997
[TBL] [Abstract][Full Text] [Related]
14. In vitro activity of telithromycin (HMR 3647) against 502 strains of anaerobic bacteria.
Wexler HM; Molitoris E; Molitoris D; Finegold SM
J Antimicrob Chemother; 2001 Apr; 47(4):467-9. PubMed ID: 11266423
[TBL] [Abstract][Full Text] [Related]
15. Bactericidal activity of ceftizoxime, cefotetan, and clindamycin against cefoxitin-resistant strains of the Bacteroides fragilis group.
Aldridge KE; Stratton CW
J Antimicrob Chemother; 1991 Nov; 28(5):701-5. PubMed ID: 1778873
[TBL] [Abstract][Full Text] [Related]
16. Levofloxacin plus metronidazole administered once daily versus moxifloxacin monotherapy against a mixed infection of Escherichia coli and Bacteroides fragilis in an in vitro pharmacodynamic model.
Hermsen ED; Hovde LB; Sprandel KA; Rodvold KA; Rotschafer JC
Antimicrob Agents Chemother; 2005 Feb; 49(2):685-9. PubMed ID: 15673752
[TBL] [Abstract][Full Text] [Related]
17. First report of metronidazole resistant, nimD-positive, Bacteroides stercoris isolated from an abdominal abscess in a 70-year-old woman.
Otte E; Nielsen HL; Hasman H; Fuglsang-Damgaard D
Anaerobe; 2017 Feb; 43():91-93. PubMed ID: 28011371
[TBL] [Abstract][Full Text] [Related]
18. Pharmacodynamics of pulse dosing versus standard dosing: in vitro metronidazole activity against Bacteroides fragilis and Bacteroides thetaiotaomicron.
Ibrahim KH; Gunderson BW; Hermsen ED; Hovde LB; Rotschafer JC
Antimicrob Agents Chemother; 2004 Nov; 48(11):4195-9. PubMed ID: 15504841
[TBL] [Abstract][Full Text] [Related]
19. In vitro activity of telithromycin (HMR 3647) and seven other antimicrobial agents against anaerobic bacteria.
Ackermann G; Schaumann R; Pless B; Claros MC; Rodloff AC
J Antimicrob Chemother; 2000 Jul; 46(1):115-9. PubMed ID: 10882699
[TBL] [Abstract][Full Text] [Related]
20. Antibiotic penetration of experimental intra-abdominal abscesses.
Galandiuk S; Lamos J; Montgomery W; Young S; Polk HC
Am Surg; 1995 Jun; 61(6):521-5. PubMed ID: 7762902
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
